Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.

Publication date: Dec 31, 2024

Concepts Keywords
2019ncov Adjuvants, Immunologic
Africa Adjuvants, Immunologic
Nct04533399 Adolescent
Vaccine Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Cross-Over Studies
Female
HIV Infections
Humans
Immunization, Secondary
Immunogenicity, Vaccine
Male
Middle Aged
Novavax, Inc.
SARS-CoV-2
South Africa
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccines, Synthetic
Vaccines, Synthetic
Young Adult

Semantics

Type Source Name
disease IDO protein
disease MESH infection
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH HIV Infections

Original Article

(Visited 1 times, 1 visits today)